NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Distribution · USD

EDAP TMS S.A. (FOCL) Stock Analysis

EDAP TMS S.A. (FOCL) is a Medical Distribution stock listed on NASDAQ and quoted in US Dollar.

FOCL

$4.15

−$0.02 (−0.48%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FOCL with… →

FOCL Key Statistics

As of Sep 4, 2026
Trading
Open
$4.18
Previous Close
$4.17
Day's Range
4.15–4.24
52-Week Range
1.75–6.40
Volume
103.14K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.07
Valuation
Market Cap
$190.70M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.40
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.04
Financials (FY)
Revenue (FY)
$70.53M+1.63%
Net Income (FY)
−$29.25M
Profit marginThe share of revenue left as profit after all costs and taxes.
−49.13%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.95M
1-Year Return
+64.68%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
102.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FOCL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+26.14%
2025+48.87%
2024−58.14%
2023−50.47%
2022+77.96%
2021+15.86%
2020+16.70%
2019+139.46%
2018−35.54%
2017−12.50%
2016 (partial year)+7.54%

As of September 4, 2026.

FOCL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$70.53M−$29.25M−41.5%
2024$69.40M−$20.58M−29.7%
2023$66.79M−$23.41M−35.0%
2022$59.10M−$3.15M−5.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$70.53M$30.00M−$24.70M−$29.25M−41.5%
2024$69.40M$28.74M−$22.23M−$20.58M−29.7%
2023$66.79M$26.98M−$21.90M−$23.41M−35.0%
2022$59.10M$25.94M−$4.57M−$3.15M−5.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FOCL Valuation vs Medical Distribution Median

Median of 13 stocks
MetricFOCLMedical Distribution medianvs median
P/S ratio2.400.366.7x the median
Profit margin−49.13%−4.03%45.1 pts below

Medians across 13 Medical Distribution stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

EDAP TMS S.A. (FOCL) is capitalised at $190.70M on the latest close. It is classified in the Medical Distribution industry, within the Healthcare sector. Headcount on file is 289.

The most recent close on file for FOCL is $4.15, dated September 4, 2026. That is −$0.02 (−0.48%) against the previous close. The 52-week range on file runs from $1.75 to $6.40. The latest close sits 137.14% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $70.53M. Against the prior fiscal year total of $69.40M, that is a change of +1.63%. The same year closed with a net loss of $29.25M. Profit margin runs at −49.13%. That is 45.1 percentage points below the Medical Distribution median of −4.03%. Earnings per share on a trailing basis come to −1.04.

Across the 4 fiscal years on file, revenue moves from $59.10M in 2022 to $70.53M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 2.4. On price-to-sales that is 6.7 times the Medical Distribution median of 0.36. The medians here are taken across 13 Medical Distribution companies that report the metric.

Over the trailing twelve months the price has returned +64.68%. Measured over 10 years, that is +3.68% a year compounded. The reported beta is −0.07. Annualized volatility over the trailing 10 years is 65.41%.

Growth & Income

No dividend is on file for FOCL.

Across the complete calendar years on file, 2019 returned +139.46% and 2024 returned −58.14%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +26.14% year to date.

Peer Comparison

EDAP TMS S.A. (FOCL) operates in the Medical Distribution industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
EDAP TMS S.A. FOCL $190.70M —
McKesson Corporation MCK $105.86B 24.3
Cencora, Inc. COR $63.15B 24.6
Cardinal Health, Inc. CAH $57.49B 34.2

The Medical Distribution industry average P/E ratio is 25.4x. EDAP TMS S.A. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Distribution Stocks

MCK

McKesson Corporation

$105.86B

 COR

Cencora, Inc.

$63.15B

 CAH

Cardinal Health, Inc.

$57.49B

 HSIC

Henry Schein, Inc.

$10.01B

 AHG

Akso Health Group

$726.49M

 QIPT

Quipt Home Medical Corp

$162.30M
View all Medical Distribution stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About EDAP TMS S.A.

EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.

Visit website →